MediciNova Inc
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2b/3 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis… Read more
MediciNova Inc (MNOV) - Net Assets
Latest net assets as of September 2025: $43.96 Million USD
Based on the latest financial reports, MediciNova Inc (MNOV) has net assets worth $43.96 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($47.58 Million) and total liabilities ($3.61 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $43.96 Million |
| % of Total Assets | 92.4% |
| Annual Growth Rate | 8.49% |
| 5-Year Change | -26.39% |
| 10-Year Change | 60.3% |
| Growth Volatility | 345.74 |
MediciNova Inc - Net Assets Trend (2001–2024)
This chart illustrates how MediciNova Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for MediciNova Inc (2001–2024)
The table below shows the annual net assets of MediciNova Inc from 2001 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $52.50 Million | -15.83% |
| 2023-12-31 | $62.38 Million | -11.20% |
| 2022-12-31 | $70.24 Million | -16.06% |
| 2021-12-31 | $83.68 Million | +17.32% |
| 2020-12-31 | $71.33 Million | -4.76% |
| 2019-12-31 | $74.89 Million | +2.44% |
| 2018-12-31 | $73.11 Million | +89.19% |
| 2017-12-31 | $38.64 Million | +11.90% |
| 2016-12-31 | $34.53 Million | +5.43% |
| 2015-12-31 | $32.75 Million | +48.81% |
| 2014-12-31 | $22.01 Million | -13.43% |
| 2013-12-31 | $25.43 Million | +70.87% |
| 2012-12-31 | $14.88 Million | -36.67% |
| 2011-12-31 | $23.50 Million | -4.89% |
| 2010-12-31 | $24.70 Million | -38.26% |
| 2009-12-31 | $40.01 Million | -16.72% |
| 2008-12-31 | $48.04 Million | -27.87% |
| 2007-12-31 | $66.61 Million | -34.04% |
| 2006-12-31 | $100.98 Million | -25.59% |
| 2005-12-31 | $135.71 Million | +1669.53% |
| 2004-12-31 | $7.67 Million | +67.82% |
| 2003-12-31 | $4.57 Million | +307.30% |
| 2002-12-31 | $1.12 Million | -86.07% |
| 2001-12-31 | $8.05 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to MediciNova Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 42475524200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $49.05K | 0.09% |
| Other Comprehensive Income | $-135.15K | -0.26% |
| Other Components | $479.34 Million | 912.97% |
| Total Equity | $52.50 Million | 100.00% |
MediciNova Inc Competitors by Market Cap
The table below lists competitors of MediciNova Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
North Media A/S
CO:NORTHM
|
$61.07 Million |
|
Deva Holding AS
IS:DEVA
|
$61.08 Million |
|
Fabryka Obrabiarek RAFAMET S.A.
WAR:RAF
|
$61.08 Million |
|
TCI Express Limited
NSE:TCIEXP
|
$61.13 Million |
|
First Northwest Bancorp
NASDAQ:FNWB
|
$61.01 Million |
|
Esprit Holdings Limited
PINK:ESHDF
|
$60.99 Million |
|
Deutsche Konsum REIT AG
XETRA:DKG
|
$60.97 Million |
|
SCG Decor PCL
BK:SCGD
|
$60.91 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in MediciNova Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 62,378,424 to 52,503,551, a change of -9,874,873 (-15.8%).
- Net loss of 11,049,549 reduced equity.
- Other comprehensive income decreased equity by 17,064.
- Other factors increased equity by 1,191,740.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-11.05 Million | -21.05% |
| Other Comprehensive Income | $-17.06K | -0.03% |
| Other Changes | $1.19 Million | +2.27% |
| Total Change | $- | -15.83% |
Book Value vs Market Value Analysis
This analysis compares MediciNova Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.35x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.01x to 1.35x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2001-12-31 | $161.08 | $1.45 | x |
| 2002-12-31 | $22.44 | $1.45 | x |
| 2003-12-31 | $91.40 | $1.45 | x |
| 2004-12-31 | $153.38 | $1.45 | x |
| 2005-12-31 | $15.20 | $1.45 | x |
| 2006-12-31 | $9.97 | $1.45 | x |
| 2007-12-31 | $5.67 | $1.45 | x |
| 2008-12-31 | $3.98 | $1.45 | x |
| 2009-12-31 | $3.31 | $1.45 | x |
| 2010-12-31 | $1.99 | $1.45 | x |
| 2011-12-31 | $1.59 | $1.45 | x |
| 2012-12-31 | $0.86 | $1.45 | x |
| 2013-12-31 | $1.23 | $1.45 | x |
| 2014-12-31 | $0.91 | $1.45 | x |
| 2015-12-31 | $1.23 | $1.45 | x |
| 2016-12-31 | $1.05 | $1.45 | x |
| 2017-12-31 | $1.10 | $1.45 | x |
| 2018-12-31 | $1.78 | $1.45 | x |
| 2019-12-31 | $1.74 | $1.45 | x |
| 2020-12-31 | $1.61 | $1.45 | x |
| 2021-12-31 | $1.72 | $1.45 | x |
| 2022-12-31 | $1.43 | $1.45 | x |
| 2023-12-31 | $1.27 | $1.45 | x |
| 2024-12-31 | $1.07 | $1.45 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently MediciNova Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -21.05%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.06x
- Recent ROE (-21.05%) is above the historical average (-88.71%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2001 | -22.29% | 0.00% | 0.00x | 1.04x | $-2.60 Million |
| 2002 | -617.74% | 0.00% | 0.00x | 1.41x | $-7.04 Million |
| 2003 | -135.87% | 0.00% | 0.00x | 1.23x | $-6.67 Million |
| 2004 | -629.44% | -9845.89% | 0.01x | 7.01x | $-49.04 Million |
| 2005 | -18.93% | -3195.27% | 0.01x | 1.05x | $-39.26 Million |
| 2006 | -35.34% | -13525.09% | 0.00x | 1.11x | $-45.79 Million |
| 2007 | -73.42% | -18.53% | 3.58x | 1.11x | $-55.56 Million |
| 2008 | -45.63% | 0.00% | 0.00x | 1.05x | $-26.73 Million |
| 2009 | -50.91% | 0.00% | 0.00x | 2.36x | $-24.37 Million |
| 2010 | -81.72% | 0.00% | 0.00x | 2.95x | $-22.66 Million |
| 2011 | -75.47% | 0.00% | 0.00x | 1.31x | $-20.08 Million |
| 2012 | -73.66% | -1365.76% | 0.04x | 1.32x | $-12.45 Million |
| 2013 | -15.84% | -67.11% | 0.20x | 1.16x | $-6.57 Million |
| 2014 | -41.78% | 0.00% | 0.00x | 1.24x | $-11.40 Million |
| 2015 | -27.01% | 0.00% | 0.00x | 1.16x | $-12.12 Million |
| 2016 | -31.47% | 0.00% | 0.00x | 1.15x | $-14.32 Million |
| 2017 | -28.89% | 0.00% | 0.00x | 1.12x | $-15.03 Million |
| 2018 | -20.07% | 0.00% | 0.00x | 1.06x | $-21.99 Million |
| 2019 | -17.28% | 0.00% | 0.00x | 1.06x | $-20.43 Million |
| 2020 | -19.42% | -346.35% | 0.05x | 1.06x | $-20.99 Million |
| 2021 | -12.11% | -251.00% | 0.05x | 1.04x | $-18.50 Million |
| 2022 | -20.03% | 0.00% | 0.00x | 1.06x | $-21.09 Million |
| 2023 | -13.74% | -857.15% | 0.02x | 1.06x | $-14.81 Million |
| 2024 | -21.05% | 0.00% | 0.00x | 1.06x | $-16.30 Million |
Industry Comparison
This section compares MediciNova Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $184,483,093
- Average return on equity (ROE) among peers: -41.08%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| MediciNova Inc (MNOV) | $43.96 Million | -22.29% | 0.08x | $61.04 Million |
| Aadi Bioscience Inc (AADI) | $136.41 Million | -80.71% | 0.16x | $17.03 Million |
| America Great Health (AAGH) | $-48.07K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $408.66 Million | -216.05% | 5.93x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $59.51 Million |
| ABIVAX Société Anonyme (AAVXF) | $48.18 Million | -23.29% | 0.12x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $740.10 Million |
| Abeona Therapeutics Inc (ABEO) | $102.55 Million | -82.14% | 0.47x | $210.89 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-11.42 Million | 0.00% | 0.00x | $117.44 Million |
| Abpro Holdings, Inc. (ABP) | $-85.14 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $316.52 Million |